Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

J & J Buying Synthes for $21.3B

April 27, 2011 6:59 am | by Frank Jordans | News | Comments

Health products giant Johnson & Johnson said it will buy U.S.-Swiss medical device maker Synthes Inc. for $21.3 billion, greatly increasing its share of the market for surgical trauma equipment and orthopedic implants.


API Toolkit

April 26, 2011 8:31 am | Product Releases | Comments

Sage-N Research, Inc. announced a new API toolkit for developers of proteomics data analysis software. The toolkit will enable software developers to add the power and sensitivity of SORCERER analyses to their existing software packages.


Syringe Pumps

April 26, 2011 8:29 am | Drug Discovery & Development | Product Releases | Comments

Harvard Apparatus has introduced a new line of OEM Syringe Pumps designed for specialized solutions for a variety of fluid handling applications to meet fluidics research requirements.


KemPharm Working With MonoSol on ADHD Treatment

April 26, 2011 8:22 am | News | Comments

KemPharm, Inc. announced that KP106 will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.


Eppendorf Opens Neurobiology Contest

April 26, 2011 8:19 am | News | Comments

Eppendorf and the world-renowned journal Science are now accepting applications for the 2011 Eppendorf & Science Prize for Neurobiology. The Eppendorf & Science Prize for Neurobiology is an annual international research prize of US$ 25,000.


High Omega-3 Levels May Boost Cancer Risk

April 26, 2011 8:10 am | News | Comments

The largest study ever to examine the association of dietary fats and prostate cancer risk has found what's good for the heart may not be good for the prostate.


New Drug Class Could Take on Colon Cancer

April 26, 2011 8:07 am | News | Comments

A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study has found.


Kuros Candidate Reduces Healing Time

April 26, 2011 8:04 am | News | Comments

Kuros Biosurgery AG, announced that KUR-113 met the primary efficacy endpoint in a 200 patient Phase 2b clinical trial designed to assess its efficacy and safety in open tibial shaft fracture patients.


FDA Approves DUEXIS for Arthritis

April 26, 2011 7:54 am | News | Comments

Horizon Pharma, Inc. announced that the U.S. Food and Drug Administration has approved DUEXIS, a novel tablet formulation containing a fixed-dose combination of ibuprofen and famotidine.


Positive Results in Remoxy Study

April 26, 2011 7:50 am | News | Comments

Pain Therapeutics Inc. reported clinical study results that may indicate its pain drug candidate Remoxy is more difficult to abuse than OxyContin. The company said patients with a history of abusing painkillers did not enjoy Remoxy as much as OxyContin.


J & J Awaits Deceptive Marketing Ruling

April 26, 2011 7:47 am | by Meg Kinnard | News | Comments

It's now up to a Spartanburg County judge to decide how much a Johnson & Johnson subsidiary should pay South Carolina for deceptive marketing of an antipsychotic drug. If the judge agrees with attorneys for the state, it could be in the billions of dollars.


Absorption Systems Publishes CellPort Study

April 26, 2011 7:44 am | News | Comments

Absorption Systems announced the results of another study demonstrating the power of the company’s CellPort Technologies to predict the potential for pharmacokinetic drug-drug interactions.


Protease Inhibitors

April 25, 2011 8:23 am | Product Releases | Comments

The ProteaseArrest family of protease inhibitor cocktails are unique ready-to-use liquid format cocktails that offer immediate >98% inhibition of harmful proteases.


3D Cell Culture

April 25, 2011 8:20 am | Product Releases | Comments

AMSBIO has announced the launch of Alvetex, a cell culture scaffold that enables genuine 3D cell culture to be grown routinely and cost-effectively.


Merck, Sanofi Team on Phase 3 Trial

April 25, 2011 8:13 am | News | Comments

Merck and Sanofi Pasteur announced the initiation of a Phase 3 clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.